Utilize este identificador para referenciar este registo: https://hdl.handle.net/10216/145239
Registo completo
Campo DCValorIdioma
dc.creatorFerreira, LB
dc.creatorGimba, E
dc.creatorVinagre, J
dc.creatorSobrinho-Simões, M
dc.creatorSoares, P
dc.date.accessioned2022-11-17T11:32:50Z-
dc.date.available2022-11-17T11:32:50Z-
dc.date.issued2020
dc.identifier.issn1661-6596
dc.identifier.urihttps://hdl.handle.net/10216/145239-
dc.description.abstractIn thyroid cancer, calcification is mainly present in classical papillary thyroid carcinoma (PTC) and in medullary thyroid carcinoma (MTC), despite being described in benign lesions and in other subtypes of thyroid carcinomas. Thyroid calcifications are classified according to their diameter and location. At ultrasonography, microcalcifications appear as hyperechoic spots = 1 mm in diameter and can be named as stromal calcification, bone formation, or psammoma bodies (PBs), whereas calcifications > 1 mm are macrocalcifications. The mechanism of their formation is still poorly understood. Microcalcifications are generally accepted as a reliable indicator of malignancy as they mostly represent PBs. In order to progress in terms of the understanding of the mechanisms behind calcification occurring in thyroid tumors in general, and in PTC in particular, we decided to use histopathology as the basis of the possible cellular and molecular mechanisms of calcification formation in thyroid cancer. We explored the involvement of molecules such as runt-related transcription factor-2 (Runx-2), osteonectin/secreted protein acidic and rich in cysteine (SPARC), alkaline phosphatase (ALP), bone sialoprotein (BSP), and osteopontin (OPN) in the formation of calcification. The present review offers a novel insight into the mechanisms underlying the development of calcification in thyroid cancer.
dc.description.sponsorshipThis research was funded by FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT—Fundação para a Ciência e a Tecnologia/Ministério daCiência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” Funding: This research was funded by FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT—Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274). Additional funding by the European Regional Development Fund (ERDF) through the Operational Programme for Competitiveness and Internationalization—COMPETE2020; Portuguese national funds via FCT, under project POCI-01-0145-FEDER-016390: CANCEL STEM; and from the FCT, under the project POCI-01-0145-FEDER-031438: The other faces of telomerase: Looking beyond tumour immortalization (PDTC/MED_ONC/31438/2017). J.V. is funded with a research contract (CEECIND/00201/2017) by Fundação para a Ciência e a Tecnologia, Ministério da Ciência, Tecnologia e Ensino Superior (FCT). This research was funded by FEDER?Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020?Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT?Funda??o para a Ci?ncia e a Tecnologia/Minist?rio da Ci?ncia, Tecnologia e Inova??o in the framework of the project ?Institute for Research and Innovation in Health Sciences? (POCI-01-0145-FEDER-007274). Additional funding by the European Regional Development Fund (ERDF) through the Operational Programme for Competitiveness and Internationalization?COMPETE2020; Portuguese national funds via FCT, under project POCI-01-0145-FEDER-016390: CANCEL STEM; and from the FCT, under the project POCI-01-0145-FEDER-031438: The other faces of telomerase: Looking beyond tumour immortalization (PDTC/MED_ONC/31438/2017). J.V. is funded with a research contract (CEECIND/00201/2017) by Funda??o para a Ci?ncia e a Tecnologia, Minist?rio da Ci?ncia, Tecnologia e Ensino Superior (FCT).
dc.language.isoeng
dc.publisherMDPI
dc.relationinfo:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC%2FMED-ONC%2F31438%2F2017/PT
dc.relation.ispartofInternational Journal of Molecular Sciences, vol.21(20):7718
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCalcifications
dc.subjectOsteopontin
dc.subjectPsammoma bodies
dc.subjectThyroid cancer
dc.subject.meshAnimals
dc.subject.meshCalcification, Physiologic
dc.subject.meshCalcinosis / genetics
dc.subject.meshHumans
dc.subject.meshModels, Biological
dc.subject.meshOsteopontin / metabolism
dc.subject.meshThyroid Gland / pathology
dc.subject.meshThyroid Neoplasms / pathology
dc.titleMolecular aspects of thyroid calcification
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3390/ijms21207718
dc.relation.publisherversionhttps://www.mdpi.com/1422-0067/21/20/7718
Aparece nas coleções:I3S - Artigo em Revista Científica Internacional

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
10.3390-ijms21207718.pdf2.58 MBAdobe PDFThumbnail
Ver/Abrir


Este registo está protegido por Licença Creative Commons Creative Commons